These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37151596)

  • 21. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
    Camenga DR; Colon-Rivera HA; Muvvala SB
    J Stud Alcohol Drugs; 2019 Jul; 80(4):393-402. PubMed ID: 31495374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
    Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
    J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
    Andraka-Christou B; Page C; Schoebel V; Buche J; Haffajee RL
    Addict Sci Clin Pract; 2022 Aug; 17(1):43. PubMed ID: 35945636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective.
    Hall NY; Le L; Majmudar I; Mihalopoulos C
    Drug Alcohol Depend; 2021 Apr; 221():108651. PubMed ID: 33667783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage.
    Calcaterra SL; Lockhart S; Natvig C; Mikulich S
    J Hosp Med; 2023 Oct; 18(10):896-907. PubMed ID: 37608527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
    Madden EF; Prevedel S; Light T; Sulzer SH
    Subst Use Misuse; 2021; 56(14):2181-2201. PubMed ID: 34538213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Substance Use, Recovery, and Non-Drug-Related Online Community Participation on the Risk of a Use Episode During Remission From Opioid Use Disorder: Longitudinal Observational Study.
    Naserianhanzaei E; Koschate-Reis M
    J Med Internet Res; 2022 Aug; 24(8):e36555. PubMed ID: 35994333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of medication-assisted treatment for opioid use disorder.
    Ghanem N; Dromgoole D; Hussein A; Jermyn RT
    J Osteopath Med; 2022 Mar; 122(7):367-374. PubMed ID: 35285220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting Patient Satisfaction With Medications for Treating Opioid Use Disorder: Case Study Applying Natural Language Processing to Reviews of Methadone and Buprenorphine/Naloxone on Health-Related Social Media.
    Omranian S; Zolnoori M; Huang M; Campos-Castillo C; McRoy S
    JMIR Infodemiology; 2023; 3():e37207. PubMed ID: 37113381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.
    Lin Q; Kolak M; Watts B; Anselin L; Pollack H; Schneider J; Taylor B
    Soc Sci Med; 2022 Jul; 305():115034. PubMed ID: 35636049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gaps in Evidence-based Treatment of Concurrent Attention Deficit Hyperactivity Disorder and Opioid Use Disorder: A Scoping Review.
    Ramey OL; Bonny AE; Silva Almodóvar A; Nahata MC
    Ann Pharmacother; 2023 Aug; 57(8):978-990. PubMed ID: 36510631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
    Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
    J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 37. Concerns among people who use opioids during the COVID-19 pandemic: a natural language processing analysis of social media posts.
    Sarker A; Nataraj N; Siu W; Li S; Jones CM; Sumner SA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):16. PubMed ID: 35248103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing an opioid use disorder treatment cascade: A review of quality measures.
    Williams AR; Nunes EV; Bisaga A; Pincus HA; Johnson KA; Campbell AN; Remien RH; Crystal S; Friedmann PD; Levin FR; Olfson M
    J Subst Abuse Treat; 2018 Aug; 91():57-68. PubMed ID: 29910015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
    Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Will My Baby Be OK?" A Qualitative Analysis of Pregnant Women's Suboxone
    Moore DJ; Butzlaff A
    J Am Psychiatr Nurses Assoc; 2023; 29(3):185-193. PubMed ID: 37038973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.